ClinicalTrials.gg

Program

ATG-022

A development code.

Its studies are led by Antengene Biologics.

Furthest: phase 3, since Aug 25, 20263 company-led studies, 3 open or runningNext primary completion: Sep 30, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Antengene Biologics33 open or runningphase 3since Aug 25, 2026Jan 17, 2023Sep 30, 2027phase 2 · NCT07327229

Also a collaborator on its studies: Merck.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 17, 2023First study: phase 1 study in Advanced/Metastatic Solid TumorsFirst studyNCT05718895 · 156 planned · Australia, China
  2. Dec 5, 2025Phase 2 study in Unresectable or Metastatic Gastric or Gastroesophageal Junction AdenocarcinomaNCT07327229 · 132 planned · China
  3. Aug 25, 2026Phase 3 study in Advanced Gastric or Gastroesophageal Junction AdenocarcinomaPhase 3 reachedNCT07795346 · 380 planned · China

Ahead

  1. Sep 30, 2027Primary completion: phase 2 study in Unresectable or Metastatic Gastric or Gastroesophageal Junction AdenocarcinomaNCT07327229
  2. Dec 30, 2027Primary completion: phase 1 study in Advanced/Metastatic Solid TumorsNCT05718895
  3. Dec 31, 2029Primary completion: phase 3 study in Advanced Gastric or Gastroesophageal Junction AdenocarcinomaNCT07795346

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07795346Advanced Gastric or Gastroesophageal Junction Adenocarcinoma · China3RecruitingDec 31, 2029380
NCT07327229Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma · China2RecruitingSep 30, 2027132
NCT05718895Advanced/Metastatic Solid Tumors · Australia, China1RecruitingDec 30, 2027156

How it is read

Names in the registry

  • “ATG-022”, 3 entries

Codes read as this program: ATG022.

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.